Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach.
Approach opens a new avenue to study the biology of acute leukemia and for the development of new drugs.
A Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients.
Michigan Medicine is the only treatment center in Michigan and one of several dozen sites in the country to offer CAR T-cell immune-therapy for treating childhood leukemia.
In a new study, researchers looked for alterations in the gut microbiome to see whether its metabolites could improve outcomes after bone marrow transplants.